` 600276 (Jiangsu Hengrui Pharmaceuticals Co Ltd) vs Shanghai Composite Comparison - Alpha Spread

600276
vs
Shanghai Composite

Over the past 12 months, has outperformed Shanghai Composite, delivering a return of 12% compared to the Shanghai Composite's 10% growth.

Stocks Performance
600276 vs Shanghai Composite

Loading

Performance Gap
600276 vs Shanghai Composite

Loading
600276
Shanghai Composite
Difference

Performance By Year
600276 vs Shanghai Composite

Loading
600276
Shanghai Composite
Add Stock

Competitors Performance
Jiangsu Hengrui Pharmaceuticals Co Ltd vs Peers

Shanghai Composite
600276
LLY
JNJ
NOVO B
ROG
Add Stock

Jiangsu Hengrui Pharmaceuticals Co Ltd
Glance View

Economic Moat
Narrow
Market Cap
324.4B CNY
Industry
Pharmaceuticals

Nestled in the throbbing economic heart of China's Jiangsu province, Jiangsu Hengrui Pharmaceuticals Co Ltd has carved a niche as a formidable player in the global pharmaceutical landscape. Established in 1970, this company has evolved from its humble beginnings into a powerhouse known for its relentless focus on research and development, a keystone in its operational strategy. Hengrui has built a diverse portfolio of products, primarily focusing on oncological, cardiovascular, and anti-diabetic therapeutics. The company leverages its state-of-the-art R&D facilities and a team of top-tier scientists to innovate and advance new treatment solutions, which are then patented to ensure exclusivity and competitive market positioning. In addition to its robust R&D-driven pipeline, Hengrui thrives through strategic collaborations and international partnerships that enhance its market reach and deepen its competitive moat. Revenue generation springs from a dual-engine model: sales of proprietary drugs and a burgeoning generic drug segment that ensures steady cash flow. Furthermore, Hengrui's ability to navigate the intricate regulatory landscapes of different countries enables it to market its innovative therapies globally, thus broadening its revenue streams. With an eye toward sustainable growth, the company continually reinvests a significant portion of its profits back into R&D, sustaining its cycle of innovation and market leadership, while also playing a vital role in meeting global healthcare needs.

Intrinsic Value
32.66 CNY
Overvaluation 36%
Intrinsic Value
Price
Back to Top